545 related articles for article (PubMed ID: 12771725)
41. Risk factors, genetic predisposition and mutations in the VHL gene in sporadic renal cell carcinoma: The Netherlands Cohort Study.
Van Dijk BA; Schouten LJ; Hulsbergen-van de Kaa CA; van Houwelingen KP; Schalken JA; Kiemeney LA; Geurts van Kessel AH; Bausch-Goldbohm RA; van den Brandt PA
IARC Sci Publ; 2002; 156():509-10. PubMed ID: 12484247
[No Abstract] [Full Text] [Related]
42. Genetic and epigenetic alterations in the von hippel-lindau gene: the influence on renal cancer prognosis.
Smits KM; Schouten LJ; van Dijk BA; Hulsbergen-van de Kaa CA; Wouters KA; Oosterwijk E; van Engeland M; van den Brandt PA
Clin Cancer Res; 2008 Feb; 14(3):782-7. PubMed ID: 18245539
[TBL] [Abstract][Full Text] [Related]
43. Molecular epidemiology of VHL gene mutations in renal cell carcinoma patients: relation to dietary and other factors.
Hemminki K; Jiang Y; Ma X; Yang K; Egevad L; Lindblad P
Carcinogenesis; 2002 May; 23(5):809-15. PubMed ID: 12016154
[TBL] [Abstract][Full Text] [Related]
44. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
Sufan RI; Jewett MA; Ohh M
Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
[TBL] [Abstract][Full Text] [Related]
45. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma.
Yao M; Yoshida M; Kishida T; Nakaigawa N; Baba M; Kobayashi K; Miura T; Moriyama M; Nagashima Y; Nakatani Y; Kubota Y; Kondo K
J Natl Cancer Inst; 2002 Oct; 94(20):1569-75. PubMed ID: 12381710
[TBL] [Abstract][Full Text] [Related]
46. Downregulation of Cap43 gene by von Hippel-Lindau tumor suppressor protein in human renal cancer cells.
Masuda K; Ono M; Okamoto M; Morikawa W; Otsubo M; Migita T; Tsuneyoshi M; Okuda H; Shuin T; Naito S; Kuwano M
Int J Cancer; 2003 Jul; 105(6):803-10. PubMed ID: 12767066
[TBL] [Abstract][Full Text] [Related]
47. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein.
Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD
Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082
[TBL] [Abstract][Full Text] [Related]
48. Molecular study of a new family with hereditary renal cell carcinoma and a translocation t(3;8)(p13;q24.1).
Meléndez B; Rodríguez-Perales S; Martínez-Delgado B; Otero I; Robledo M; Martínez-Ramírez A; Ruiz-Llorente S; Urioste M; Cigudosa JC; Benítez J
Hum Genet; 2003 Feb; 112(2):178-85. PubMed ID: 12522559
[TBL] [Abstract][Full Text] [Related]
49. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations.
Maher ER; Webster AR; Richards FM; Green JS; Crossey PA; Payne SJ; Moore AT
J Med Genet; 1996 Apr; 33(4):328-32. PubMed ID: 8730290
[TBL] [Abstract][Full Text] [Related]
50. Somatic mosaicism in von Hippel-Lindau Disease.
Murgia A; Martella M; Vinanzi C; Polli R; Perilongo G; Opocher G
Hum Mutat; 2000 Jan; 15(1):114. PubMed ID: 10612832
[TBL] [Abstract][Full Text] [Related]
51. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
52. [VHL, angiogenesis and renal carcinoma: the puzzle is complete].
Richard S
Ann Pathol; 2000 Mar; 20(2):107-9. PubMed ID: 10740003
[No Abstract] [Full Text] [Related]
53. Distinct patterns of chromosomal losses in clinically synchronous and asynchronous bilateral renal cell carcinoma.
Kito H; Suzuki H; Igarashi T; Tobe T; Mizoguchi K; Kamiya N; Ichikawa T; Ito H
J Urol; 2002 Dec; 168(6):2637-40. PubMed ID: 12442000
[TBL] [Abstract][Full Text] [Related]
54. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
[TBL] [Abstract][Full Text] [Related]
55. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
56. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters.
Kondo K; Yao M; Yoshida M; Kishida T; Shuin T; Miura T; Moriyama M; Kobayashi K; Sakai N; Kaneko S; Kawakami S; Baba M; Nakaigawa N; Nagashima Y; Nakatani Y; Hosaka M
Genes Chromosomes Cancer; 2002 May; 34(1):58-68. PubMed ID: 11921283
[TBL] [Abstract][Full Text] [Related]
57. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas.
Shuin T; Kondo K; Torigoe S; Kishida T; Kubota Y; Hosaka M; Nagashima Y; Kitamura H; Latif F; Zbar B
Cancer Res; 1994 Jun; 54(11):2852-5. PubMed ID: 8187067
[TBL] [Abstract][Full Text] [Related]
58. Somatic von Hippel-Lindau gene mutations detected in sporadic endolymphatic sac tumors.
Vortmeyer AO; Huang SC; Koch CA; Governale L; Dickerman RD; McKeever PE; Oldfield EH; Zhuang Z
Cancer Res; 2000 Nov; 60(21):5963-5. PubMed ID: 11085513
[TBL] [Abstract][Full Text] [Related]
59. VHL tumor suppressor gene: its mutation and protein level in renal cell carcinoma.
Tsutsumi H; Miyamoto C; Furuichi Y; Yoshiike M; Nozawa S; Iwamoto T
Oncol Rep; 2003; 10(5):1357-61. PubMed ID: 12883707
[TBL] [Abstract][Full Text] [Related]
60. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
